Download PDF
Semin Respir Crit Care Med 2002; 23(2): 115-126
DOI: 10.1055/s-2002-25375
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Pulmonary Alveolar Proteinosis: Recent Advances

Peter J. Mazzone, Mary Jane Thomassen, Mani S. Kavuru
  • Department of Pulmonary & Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio
Further Information

Publication History

Publication Date:
24 April 2002 (online)

    Permissions and Reprints

ABSTRACT

Pulmonary Alveolar Proteinosis (PAP) is characterized by the accumulation of surfactant phospholipids and proteins within the alveoli of lungs. Currently, no specific therapy exists for PAP, and sequential whole lung lavage is standard treatment. Over the past 5 years, important advances have been made in our understanding of alveolar proteinosis, offering new directions for research as well as patient management. First, genetically altered mice that are homozygous for a disrupted granulocyte-macrophage colony-stimulating factor (GM-CSF) gene developed a lung lesion with histologic resemblance to PAP, along with normal hematopoiesis. The biochemical properties of the material filling the airspaces in these mutant mice are similar to those of patients with PAP. Surfactant is thought to be cleared or catabolized mostly by alveolar macrophages, a process dependent on GM-CSF. Second, a neutralizing autoantibody against GM-CSF was found in bronchoalveolar lavage fluid and serum of patients with idiopathic PAP, but not healthy controls. These observations raise the previously unsuspected notion that human alveolar proteinosis may be an autoimmune disease, and suggest that GM-CSF antibody has a potential role as a diagnostic test. The relationship between the antibody and disease pathogenesis remains unknown. Additional data suggest that exogenous therapy with GM-CSF may improve the lung disease in some patients with PAP. Intervention directed at treating a relative GM-CSF deficiency or lowering the antibody (i.e., by plasmapheresis or immunosuppression) may have promise in the therapy of this disease. Alveolar proteinosis may be the first human disease wherein a circulating antibody against a growth factor is linked to disease pathogenesis. Over a relatively short time, studies from ``knock-out'' mice have been translated to human studies for a new approach to diagnosis and therapy for this disease.

KEYWORD

Pulmonary alveolar proteinosis - GM-CSF - surfactant - autoimmune disease - antibody

REFERENCES

  • 1 Rosen S H, Castleman B, Liebow A A. Pulmonary alveolar proteinosis.  N Engl J Med . 1958;  258(23) 1123-1142
    CrossrefPubMedGoogle Scholar
  • 2 Goldstein L S, Kavuru M S, Curtis-McCarthy, et al. Pulmonary alveolar proteinosis: clinical features and outcomes.  Chest . 1998;  114(5) 1357-1362
    CrossrefPubMedGoogle Scholar
  • 3 Dranoff G, Crawford A D, Sadelain M, Ream B, Mulligan R C. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis.  Science . 1994;  264 713-716
    CrossrefPubMedGoogle Scholar
  • 4 Stanley E, Lieschke G J, Grail D. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.  Proc Natl Acad Sci . 1994;  91 5592-5596
    PubMedGoogle Scholar
  • 5 Kitamura T, Tanaka N, Watanabe J. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.  J Exp Med . 1999;  190(6) 875-880
    CrossrefPubMedGoogle Scholar
  • 6 Thomassen M J, Yi T, Raychaudhuri B, Malur A, Kavuru M S. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect.  Clin Immunology . 2000;  95(2) 85-92
    PubMedGoogle Scholar
  • 7 Prakash U BS, Barham S S, Carpenter H A, Dines D E, Marsh H M. Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review.  Mayo Clin Proc . 1987;  62 499-518
    CrossrefPubMedGoogle Scholar
  • 8 Asamoto H, Kitaichi M, Nishimura K, Itoh H, Izumi T. Primary pulmonary alveolar proteinosis: clinical observation of 68 patients in Japan.  Jpn J Thorac Dis . 1995;  33 835-845
    PubMedGoogle Scholar
  • 9 Rubinstein I, Mullen B M, Hoffstein V. Morphologic diagnosis of idiopathic pulmonary alveolar lipoproteinosis-revisited.  Arch Intern Med . 1988;  148 813-816
    CrossrefPubMedGoogle Scholar
  • 10 Rogers R M, Levin D C, Gray B A, Moseley L W. Physiologic effects of bronchopulmonary lavage in alveolar proteinosis.  Am Rev Respir Dis . 1978;  118 255-264
    PubMedGoogle Scholar
  • 11 Robertson H E. Pulmonary alveolar proteinosis.  Canad Med Ass J . 1965;  93 980-983
    PubMedGoogle Scholar
  • 12 Oka S, Shiraishi K, Ogata K. The course of the first case in Japan of pulmonary alveolar proteinosis.  Am Rev Respir Dis . 1966;  93(4) 608-611
    PubMedGoogle Scholar
  • 13 Spevak-Marinkovic L, Rogulja P, Ilic V. Pulmonary alveolar proteinosis.  Am Rev Respir Dis . 1967;  65(2) 295-297
    PubMedGoogle Scholar
  • 14 Teja K, Cooper P H, Squires J E, Schnatterly P T. Pulmonary alveolar proteinosis in four siblings.  N Engl J Med . 1981;  305(23) 1390-1392
    PubMedGoogle Scholar
  • 15 Webster J R, Battifora H, Furey C, Harrison R A, Shapiro B. Pulmonary alveolar proteinosis in two siblings with decreased immunoglobulin A.  Am J Med . 1980;  69 786-789
    CrossrefPubMedGoogle Scholar
  • 16 Ben-Dov I, Kishinevski Y, Roznman J. Pulmonary alveolar proteinosis in Israel: ethnic clustering.  Israel Med Assoc J . 1999;  1 75-78
    PubMedGoogle Scholar
  • 17 Hoffman R M, Rogers R M. Pulmonary alveolar proteinosis. In: Bone RC, Dantzker DR, eds. Pulmonary and Critical Care Medicine Vol 2. St. Louis: Mosby Year Book 1993: 1-7
    Google Scholar
  • 18 Carnovale R, Zornoza J, Goldman A M, Luna M. Pulmonary alveolar proteinosis: its association with hematologic malignancy and lymphoma.  Radiology . 1977;  122 303-306
    PubMedGoogle Scholar
  • 19 Aymard J P, Gyger M, Lavallee R, Legresley L P, Desy M. A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia.  Cancer . 1984;  53 954-956
    PubMedGoogle Scholar
  • 20 Cordonnier C, Fleury-Feith J, Escudier E, Atassi K, Bernaudin J F. Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients.  Am J Respir Crit Care Med . 1994;  149 788-794
    CrossrefPubMedGoogle Scholar
  • 21 Gacouin A, Le Tulzo Y, Suprin E. Acute respiratory failure caused by secondary alveolar proteinosis in a patient with acute myeloid leukemia: a case report.  Intensive Care Med . 1998;  24 265-267
    CrossrefPubMedGoogle Scholar
  • 22 Buechner H A, Ansari A. Acute silicoproteinosis: a new pathologic variant of acute silicosis in sandblasters characterized by histologic features resembling alveolar proteinosis.  Dis Chest . 1969;  55 274-284
    PubMedGoogle Scholar
  • 23 Miller R R, Churg A M, Hutcheon M, Lam S. Pulmonary alveolar proteinosis and aluminum dust exposure.  Am Rev Respir Dis . 1984;  130 312-315
    PubMedGoogle Scholar
  • 24 Xipell J M, Ham K N, Price C G, Thomas D P. Acute silicoproteinosis.  Thorax . 1977;  32 104-111
    PubMedGoogle Scholar
  • 25 Keller C A, Frost A, Cagle P T, Abraham J L. Pulmonary alveolar proteinosis in a painter with elevated pulmonary concentrations of titanium.  Chest . 1995;  108(1) 277-280
    CrossrefPubMedGoogle Scholar
  • 26 Dawkins S A, Gerhard H, Nevin M. Pulmonary alveolar proteinosis: a possible sequel of NO2 exposure.  J Occup Med . 1991;  33(5) 638-641
    PubMedGoogle Scholar
  • 27 Tran Van Nhieu J, Vojtek A M, Bernaudin J F, Escudier E, Fleury-Feith J. Pulmonary alveolar proteinosis associated with pneumocystis carinii: ultrastructural identification in bronchoalveolar lavage in AIDS and immunocompromised non-AIDS patients.  Chest . 1990;  98(4) 801-805
    CrossrefPubMedGoogle Scholar
  • 28 Ruben F L, Talamo T S. Secondary pulmonary alveolar proteinosis occurring in two patients with acquired immune deficiency syndrome.  Am J Med . 1986;  80 1187-1190
    CrossrefPubMedGoogle Scholar
  • 29 Reyes J M, Putong P B. Association of pulmonary alveolar lipoproteinosis with mycobacterial infection.  Am J Clin Pathol . 1980;  74 478-485
    PubMedGoogle Scholar
  • 30 Witty L A, Tapson V F, Piantadosi C A. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis.  Medicine . 1994;  73(2) 103-109
    CrossrefPubMedGoogle Scholar
  • 31 Couderc L J, Bernaudin J F, Epardeau B, Caubarrere I. Pulmonary alveolar proteinosis and disseminated mycobacterium avium infection [letter].  Resp Med . 1996;  90(10) 641-642
    PubMedGoogle Scholar
  • 32 Bakhos R, Gattuso P, Arcot C, Reddy V B. Pulmonary alveolar proteinosis: an unusual association with mycobacterium avium-intracellulare infection and lymphocytic interstitial pneumonia.  South Med J . 1996;  89(8) 801-802
    CrossrefPubMedGoogle Scholar
  • 33 Pascual J, Gomez Aguinaga A M, Vidal R. Alveolar proteinosis and nocardiosis: a patient treated by bronchopulmonary lavage.  Postgrad Med J . 1989;  65 674-677
    PubMedGoogle Scholar
  • 34 Gumpert B C, Nowacki M R, Amundson D E. Pulmonary alveolar lipoproteinosis: remission after antibiotic treatment.  West J Med . 1994;  161(1) 66-68
    PubMedGoogle Scholar
  • 35 Claypool W D, Rogers R M, Matuschak G M. Update on the clinical diagnosis, management, and pathogenesis of pulmonary alveolar proteinosis (phospholipidosis).  Chest . 1984;  85(4) 550-558
    PubMedGoogle Scholar
  • 36 Merino-Angulo A, Perez-Marti M, Diaz de Otazu R. Pulmonary alveolar phospholipoproteinosis associated with amyloidosis [letter].  Chest . 1990;  98(4) 1048
    PubMedGoogle Scholar
  • 37 Yousem S A. Alveolar lipoproteinosis in lung allograft recipients.  Hum Pathol . 1997;  28 1383-1386
    CrossrefPubMedGoogle Scholar
  • 38 Anton H C, Gray B. Pulmonary alveolar proteinosis presenting with pneumothorax.  Clin Radiol . 1967;  18 428-431
    CrossrefPubMedGoogle Scholar
  • 39 Olivia P B, Vogel J HK. Reactive pulmonary hypertension in alveolar proteinosis.  Chest . 1970;  58(2) 167-169
    PubMedGoogle Scholar
  • 40 Ramirez-R J. Pulmonary alveolar proteinosis: treatment by massive bronchopulmonary lavage.  Arch Intern Med . 1967;  119(2) 147-156
    CrossrefPubMedGoogle Scholar
  • 41 Godwin J D, Muller N L, Takasugi J E. Pulmonary alveolar proteinosis: CT findings.  Radiology . 1988;  169 609-613
    PubMedGoogle Scholar
  • 42 Murch C R, Carr D H. Computed tomography appearances of pulmonary alveolar proteinosis.  Clinical Radiology . 1989;  40 240-243
    CrossrefPubMedGoogle Scholar
  • 43 Johkoh T, Itoh H, Muller N L. Crazy-paving appearance at thin-section CT: spectrum of disease and pathologic findings.  Radiology . 1999;  211 155-160
    CrossrefPubMedGoogle Scholar
  • 44 Lee K, Levin D L, Webb W R. Pulmonary alveolar proteinosis: high-resolution CT, chest radiographic, and functional correlations.  Chest . 1997;  111(4) 989-995
    CrossrefPubMedGoogle Scholar
  • 45 Yeh S DJ, Whit D A, Stover-Pepe D E. Abnormal gallium scintigraphy in pulmonary alveolar proteinosis.  Clin Nuclear Med . 1987;  12 294-297
    PubMedGoogle Scholar
  • 46 Murayama J, Fukuda K, Sato T. Pulmonary alveolar proteinosis: Xe-133 scintigraphic findings before and after bronchopulmonary lavage.  Clin Nuclear Med . 1993;  18(2) 123-125
    PubMedGoogle Scholar
  • 47 Martin R J, Rogers R M, Myers N M. Pulmonary alveolar proteinosis: shunt franction and lactic acid dehydrogenase concentration as aids to diagnosis.  Am Rev Resp Dis . 1978;  117 1059-1062
    PubMedGoogle Scholar
  • 48 Hoffman R M, Rogers R M. Serum and lavage lactate dehydrogenates isoenzymes in pulmonary alveolar proteinosis.  Am Rev Respir Dis . 1991;  143 42-46
    PubMedGoogle Scholar
  • 49 Takahashi T, Munakata M, Suzuki I, Kawakami Y. Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis.  Am J Respir Crit Care Med . 1998;  158 1294-1298
    PubMedGoogle Scholar
  • 50 Nakajima M, Manabe T, Niki Y, Matsushima T. Serum KL-6 level as a monitoring marker in a patient with pulmonary alveolar proteinosis.  Thorax . 1998;  53(9) 809-811
    PubMedGoogle Scholar
  • 51 Kuroki Y, Tsutahara S, Shijubo N. Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis.  Am Rev Respir Dis . 1993;  147 723-729
    PubMedGoogle Scholar
  • 52 Masuda T, Shimura S, Sasaki H, Takishima T. Surfactant apoprotein-A concentration in sputum for diagnosis of pulmonary alveolar proteinosis.  Lancet . 1991;  337 580-582
    CrossrefPubMedGoogle Scholar
  • 53 Honda Y, Kuroki Y, Matsuura E. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids.  Am J Respir Crit Care Med . 1995;  152 1860-1866
    CrossrefPubMedGoogle Scholar
  • 54 McClenahan J B, Mussenden R. Pulmonary alveolar proteinosis.  Arch Intern Med . 1974;  133 284-287
    CrossrefPubMedGoogle Scholar
  • 55 Doyle I R, Davidson K G, Barr H A. Quantity and structure of surfactant proteins vary among patients with alveolar proteinosis.  Am J Respir Crit Care Med . 1998;  157 658-664
    CrossrefPubMedGoogle Scholar
  • 56 Alberti A, Luisetti M, Braschi A. Bronchoalveolar lavage fluid composition in alveolar proteinosis: early changes after therapeutic lavage.  Am J Respir Crit Care Med . 1996;  154 817-820
    PubMedGoogle Scholar
  • 57 Honda Y, Takahashi H, Shijubo N, Kuroki Y, Akino T. Surfactant protein-A concentration in bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis.  Chest . 1993;  103 496-499
    PubMedGoogle Scholar
  • 58 Shen H, Duan C, Li Z, Suzuki Y. Effects of proteinosis surfactant proteins on the viability of rat alveolar macrophages.  Am J Respir Crit Care Med . 1997;  156 1679-1687
    PubMedGoogle Scholar
  • 59 Crouch E, Persson A, Chang D. Accumulation of surfactant protein D in human pulmonary alveolar proteinosis.  Am J Pathol . 1993;  142 241-248
    PubMedGoogle Scholar
  • 60 Milleron B J, Costabel U, Teschler H. Bronchoalveolar lavage cell data in alveolar proteinosis.  Am Rev Respir Dis . 1991;  144 1330-1332
    CrossrefPubMedGoogle Scholar
  • 61 Singh G, Katyal S L, Bedrossian C WM, Rogers R M. Pulmonary alveolar proteinosis: staining for surfactant apoprotein in alveolar proteinosis and in conditions simulating it.  Chest . 1983;  83(1) 82-86
    CrossrefPubMedGoogle Scholar
  • 62 Mikami T, Yamamoto Y, Yokoyama M, Okayasu I. Pulmonary alveolar proteinosis: diagnosis using routinely processed smears of bronchoalveolar lavage fluid.  J Clin Pathol . 1997;  50 981-984
    PubMedGoogle Scholar
  • 63 Hawgood S. Surfactant: composition, structure and metabolism. In: Crystal RG, West JB, eds. The Lung: Scientific Foundations Philadelphia: Lippincott-Raven Publishers 1997: 247-261
    Google Scholar
  • 64 Wright J R, Youmans D C. Degradation of surfactant lipids and surfactant protein A by alveolar macrophages in vitro.  Am J Physiol . 1995;  268 L772-L780
    PubMedGoogle Scholar
  • 65 Reed J A, Whitsett J A. Granulocyte-macrophage colony-stimulating factor and pulmonary surfactant homeostasis.  Proc Assoc Am Physicians . 1998;  110(5) 321-332
    PubMedGoogle Scholar
  • 66 Wright J R. Clearance and recycling of pulmonary surfactant.  Am J Physiol 1990;259(Lung Cell Mol Physiol 3):L1-L12.
    PubMedGoogle Scholar
  • 67 Golde D W, Territo M, Finley T N, Cline M J. Defective lung macrophages in pulmonary alveolar proteinosis.  Ann Intern Med . 1976;  85 304-309
    PubMedGoogle Scholar
  • 68 Harris J O. Pulmonary alveolar proteinosis: abnormal in vitro function of alveolar macrophages.  Chest . 1979;  76(2) 156-159
    PubMedGoogle Scholar
  • 69 Nugent K M, Pesanti E L. Macrophage function in pulmonary alveolar proteinosis.  Am Rev Respir Dis . 1983;  127 780-781
    PubMedGoogle Scholar
  • 70 Gonzalez-Rothi R J, Harris J O. Pulmonary alveolar proteinosis: further evaluation of abnormal alveolar macrophages.  Chest . 1986;  90(5) 656-661
    CrossrefPubMedGoogle Scholar
  • 71 Ikegami M, Ueda T, Hull W. Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation.  Am J Physiol 1996;270(Lung Cell Mol Physiol 14):L650-L658 .
    PubMedGoogle Scholar
  • 72 Huffman J A, Hull W M, Dranoff G, Mulligan R C, Whitsett J A. Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice.  J Clin Invest . 1996;  97 649-655
    CrossrefPubMedGoogle Scholar
  • 73 Nishinakamura R, Wiler R, Dirksen U. The pulmonary alveolar proteinosis in granulocyte macrophage colony-stimulating factor/interleukins 3/5 βc receptor-deficient mice is reversed by bone marrow transplantation.  J Exp Med . 1996;  183 2657-2662
    CrossrefPubMedGoogle Scholar
  • 74 Cooke K R, Nishinakamura R, Martin T R. Persistence of pulmonary pathology and abnormal lung function in IL-3/GM-CSF/IL-5 βc receptor-deficient mice despite correction of alveolar proteinosis after BMT.  Bone Marrow Transplant . 1997;  20 657-662
    CrossrefPubMedGoogle Scholar
  • 75 Reed J A, Ikegami M, Cianciolo E R. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice.  Am J Physiol (Lung Cell Mol Physiol 20) . 1999;  276 L556-L563
    PubMedGoogle Scholar
  • 76 Carraway M S, Ghio A J, Carter J D, Piantadosi C A. Detection of granulocyte-macrophage colony stimulating factor in patients with pulmonary alveolar proteinosis.  Am J Respir Crit Care Med . 2000;  161 1294-1299
    CrossrefPubMedGoogle Scholar
  • 77 Kavuru M S, Sullivan E J, Piccin R, Thomassen M J, Stoller J K. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis.  Am J Respir Crit Care Med . 2000;  161 1143-1148
    CrossrefPubMedGoogle Scholar
  • 78 Seymour J F, Begley C G, Dirksen U. Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis.  Blood . 1998;  92(8) 2657-2667
    PubMedGoogle Scholar
  • 79 Tchou-Wong K, Harkin T J, Chi C, Bodkin M, Rom W N. GM-CSF gene expression is normal but protein release is absent in a patient with pulmonary alveolar proteinosis.  Am J Respir Crit Care Med . 1997;  156 1999-2002
    PubMedGoogle Scholar
  • 80 Seymour J F, Dunn A R, Vincent J M, Presneill J J, Pain M C. Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis.  N Engl J Med . 1996;  335(25) 1924-1925
    CrossrefPubMedGoogle Scholar
  • 81 Schock O D, Nierhoff N, Dubach H U. Treatment of pulmonary alveolar proteinosis (PAP): is GM-CSF an option?.  Eur Respir J . 1998;  131S
    PubMedGoogle Scholar
  • 82 Kitamura T, Uchida K, Tanaka N. Serological diagnosis of idiopathic pulmonary alveolar proteinosis.  Am J Respir Crit Care Med . 2000;  162 658-662
    CrossrefPubMedGoogle Scholar
  • 83 Meager A, Wadhwa M, Bird C. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease.  Immunol . 1999;  97 526-532
    PubMedGoogle Scholar
  • 84 Svenson M, Hansen M G, Ross C. Antibody to granulocyte-macrophage colony stimulating factor is a dominant anti-cytokine activity in human IgG preparations.  Blood . 1998;  91 2054-2061
    PubMedGoogle Scholar
  • 85 Nishinakamura R, Nakayama N, Hirabayashi Y. Mice deficient for the IL-3/GM-CSF/IL-5 Bc receptor exhibit lung pathology and impaired immune response, while βIL-3 receptor deficient mice are normal.  Immunity . 1995;  2 211-222
    CrossrefPubMedGoogle Scholar
  • 86 Ikegami M, Whitsett J A, Chroneos Z C. IL-4 increases surfactant and regulates metabolism in vivo.  Am J Physiol (Lung Cell Mol Physiol) . 2000;  278 L75-L80
    PubMedGoogle Scholar
  • 87 Dirksen U, Nishinakamura R, Groneck P. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common β chain expression.  J Clin Invest . 1997;  100 2211-2217
    CrossrefPubMedGoogle Scholar
  • 88 Dirksen U, Hattenhorst U, Schneider P. Defective expression of granulocyte-macrophage colony-stimulating factor/interleukin-5 receptor common β chain in children with acute myeloid leukemia associated with respiratory failure.  Blood . 1998;  92(4) 1097-1103
    PubMedGoogle Scholar
  • 89 Nogee L M, deMello D E, Dehner L P, Colten H R. Brief report: deficiency of pulmonary surfactant B in congential alveolar proteinosis.  N Engl J Med . 1993;  328 406-410
    CrossrefPubMedGoogle Scholar
  • 90 Nogee L M, Garnier G, Dietz H C. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds.  J Clin Invest . 1994;  93 1860-1863
    PubMedGoogle Scholar
  • 91 Bewig B, Wang X-D, Kirsten D, Dalhoff K, Schafer H. GM-CSF and GM-CSF Bc receptor in adult patients with pulmonary alveolar proteinosis.  Eur Respir J . 2000;  15 350-357
    CrossrefPubMedGoogle Scholar
  • 92 Farca A, Maher G, Miller A. Pulmonary alveolar proteinosis: home treatment with intermittent positive pressure breathing.  JAMA . 1973;  224(9) 1283-1285
    CrossrefPubMedGoogle Scholar
  • 93 Diaz J P, Manresa Presas F, Benasco, et al. Response to surfactant activator (Ambroxol) in alveolar proteinosis [letter].  Lancet . 1984;  1(8384) 1023
    PubMedGoogle Scholar
  • 94 Jay S J. Pulmonary alveolar proteinosis: successful treatment with aerosolized trypsin.  Am J Med . 1979;  66 348-354
    CrossrefPubMedGoogle Scholar
  • 95 Riker J B, Wolinsky H. Trypsin aerosol treatment of pulmonary alveolar proteinosis.  Am Rev Respir Dis . 1973;  108(1) 108-113
    PubMedGoogle Scholar
  • 96 Ramirez-R J, Kieffer R F, Ball W C. Bronchopulmonary lavage in man.  Ann Intern Med . 1965;  63(5) 819-828
    PubMedGoogle Scholar
  • 97 Anonymous. Alveolar proteinosis treated: total lung lavage proves successful [letter].  JAMA . 1966;  196(12) 39
    PubMedGoogle Scholar
  • 98 Kao D, Wasserman K, Costley D, Benfield J R. Advances in the treatment of pulmonary alveolar proteinosis.  Am Rev Respir Dis . 1975;  111(3) 361-363
    PubMedGoogle Scholar
  • 99 Bracci L. Role of physical therapy in management of pulmonary alveolar proteinosis.  Physical Therapy . 1988;  68(5) 686-689
    PubMedGoogle Scholar
  • 100 Hammon W E, McCaffree R, Cucchiara A J. A comparison of manual to mechanical chest percussion for clearance of alveolar material in patients with pulmonary alveolar proteinosis (phospholipidosis).  Chest . 1993;  103(5) 1409-1412
    CrossrefPubMedGoogle Scholar
  • 101 Bingisser R, Kaplan V, Zollinger A, Russi E. Whole-lung lavage in alveolar proteinosis by a modified lavage technique.  Chest . 1998;  113(6) 1718-1719
    CrossrefPubMedGoogle Scholar
  • 102 Hurrion E M, Pearson G A, Firmin R K. Extracorporeal membrane oxygenation with total cardiopulmonary support during bronchopulmonary lavage.  Chest . 1994;  106(2) 638-640
    PubMedGoogle Scholar
  • 103 Sivitanidis E, Tosson R, Wiebalck A, Laczkovics A. Combination of extracorporeal membrane oxygenation (ECMO) and pulmonary lavage in a patient with pulmonary alveolar proteinosis.  European J Cardio-thoracic Surg . 1999;  15 370-372
    PubMedGoogle Scholar
  • 104 Jansen H M, Zuurmond W WA, Roos C M, Schreuder J J, Bakker D J. Whole-lung lavage under hyperbaric oxygen conditions for alveolar proteinosis with respiratory failure.  Chest . 1987;  91(6) 829-832
    PubMedGoogle Scholar
  • 105 Nagasake Y, Takahashi M, Ueshima H, Tohda Y, Nakajima S. Bronchoalveolar lavage with trypsin in proteinosis.  Thorax . 1996;  51(7) 769-770
    PubMedGoogle Scholar
  • 106 Gale E M, Karlinsky J B, Robins A G. Bronchopulmonary lavage in pulmonary alveolar proteinosis: chest radiograph observations.  Am J Radiol . 1986;  146 981-985
    PubMedGoogle Scholar
  • 107 Hoffman R M, Dauber J H, Rogers R M. Improvement in alveolar macrophage migration after therapeutic whole lung lavage in pulmonary alveolar proteinosis.  Am Rev Respir Dis . 1989;  139 1030-1032
    PubMedGoogle Scholar
  • 108 Selecky P A, Wasserman K, Benfield J R, Lippmann M. The clinical and physiological effect of whole-lung lavage in pulmonary alveolar proteinosis: a ten-year experience.  Ann Thoracic Surg . 1977;  24(5) 451-460
    PubMedGoogle Scholar
  • 109 Torresin M, Zimmermann L JI, Cogo P E. Exogenous surfactant kinetics in infant respiratory distress syndrome: a novel method with stable isotopes.  Am J Respir Crit Care Med . 2000;  161 1584-1589
    PubMedGoogle Scholar
  • 110 Wylam M E, Ten R M, Katzmann J A. Aerosolized GM-CSF improves pulmonary function in idiopathic pulmonary alveolar proteinosis.  Am J Respir Crit Care Med . 2000;  161 A889
    PubMedGoogle Scholar
  • 111 Gaine S P, O'Marcaigh A S. Pulmonary alveolar proteinosis: lung transplant or bone marrow transplant [letter].  Chest . 1998;  113(2) 563-564
    PubMedGoogle Scholar
  • 112 Alden P L, Novotny D B. Recurrent alveolar proteinosis following double lung transplantation.  Chest . 1997;  111(5) 1457-1458
    PubMedGoogle Scholar